**Exhibit 31.1****CERTIFICATION**     I, Daniel B. Carr, M.D., Chief Executive Officer and Chief Medical Officer of JavelinPharmaceuticals, Inc. (the “Company”), certify that:     1. I have reviewed this Amendment No. 1 to Annual Report on Form 10-K of the Company.     2. Based on my knowledge, this report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading with respect to the periodcovered by this report.     3. Based on my knowledge, the financial statements, and other financial information includedin this report, fairly present in all material respects the financial condition, results ofoperations and cash flows of the Company as of, and for, the periods presented in this report.     4. The Company’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules13a-15(f) and 15d-15(f)) for the Company and have: a) Designed such disclosure controls and procedures, or causedsuch disclosure controls and procedures to be designated under oursupervision, to ensure that material information relating to the Company,including its consolidated subsidiaries, is made known to us by others withinthose entities, particularly during the period in which this report is beingprepared;  b) Designed such internal control over financial reporting, orcaused such internal control over financial reporting to be designed under oursupervision, to provide reasonable assurance regarding the reliability offinancial reporting and the preparation of financial statements for externalpurposes in accordance with generally accepted accounting principles;  c) Evaluated the effectiveness of the Company’s disclosurecontrols and procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of theperiod covered by this report based on such evaluation; and  d) Disclosed in this report any change in the Company’s internalcontrol over financial reporting that occurred during the Company’s mostrecent fiscal quarter (the Company’s fourth quarter in the case of an annualreport) that has materially affected, or is reasonably likely to materiallyaffect, the Company’s internal control over financial reporting.     5. The Company’s other certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the Company’s auditors and the auditcommittee of the Company’s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in thedesign or operation of internal control over financial reporting which arereasonably likely to adversely affect the Company’s ability to record,process, summarize and report financial information; and
 

 
 b) Any fraud, whether or not material, that involves managementor other employees who have a significant role in the Company’s internalcontrol over financial reporting.     Date: May 9, 2007 /s/ Daniel B. Carr, M.D.     Name: Daniel B. Carr, M.D.  Title: Chief Executive Officer and    Chief Medical Officer